HOME
• levitra take
• levitra ldl
• levitra viagra cialis compare
• levitra patent india

levitra patient information leaflets

Drug Interactions Effect of other drugs on Levitra In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 (CYP) isoforms 3A4/5, and to a lesser degree by CYP2C9. Possible food and drug interactions when taking Levitra Be sure to check with your doctor about the medications that should never be taken with Levitra, including: Alpha-blocking drugs prescribed for high blood pressure or prostate problems, including doxazosin, tamsulosin, terazosin, prazosin, and alfuzosin Nitrate-based drugs prescribed for chest pain, such as nitroglycerin patches, nitroglycerin ointment, nitroglycerin pills, and isosorbide pills Street drugs known as "poppers," including amyl nitrate and butyl nitrate If Levitra is taken with certain other drugs, levitra patient information leaflets effects of either could be increased, decreased, or altered. In the moderate (CLcr = 30-50 ml/min) or severe (CLcr<30 ml/min) renal impairment groups, the AUC levitra patient information leaflets vardenafil was 20–30% higher compared levitra patient information leaflets that observed in a control group with normal renal function (CLcr>80 ml/min). You may report side effects to levitra patient information leaflets at 1-800-FDA-1088. During sexual activity, if you become dizzy or nauseated, or have pain, numbness, or tingling in your chest, arms, neck, or jaw, stop levitra patient information leaflets call your doctor right away. It is not possible to levitra patient information leaflets whether these events are related directly to the use of PDE5 inhibitors or to other factors (see ADVERSE REACTIONS). Ask your doctor or pharmacist if you are not sure if any of your medicines are nitrates. One patient experienced a decrease from baseline in standing SBP of >30 mmHg following vardenafil 10 mg.

Go To...

• test levitra
• levitra empty stomach
• patent expiration levitra
• levitra germany
• levitra how to use

levitra patient information leaflets

There were no severe adverse events related to hypotension reported during the study. Less serious Levitra side effects may include: warmth or redness in your face, neck, or chest; stuffy nose; headache; memory problems; upset stomach; or back pain. Do not take in larger or smaller amounts or for longer than recommended. It may also be used for other conditions as determined by your doctor. A postmarketing study evaluating the effect of combining Levitra with another drug of comparable QT effect showed an additive QT effect when compared with either drug alone (see CLINICAL PHARMACOLOGY,Electrophysiology). Printed in U.S.A. Vardenafil pharmacokinetics have not been evaluated in patients requiring renal dialysis. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. The dose may levitra patient information leaflets increased to a maximum recommended dose of 20 mg or decreased to levitra patient information leaflets mg based on efficacy and side effects. General levitra patient information leaflets side effects have included accidental injury (3%) and flu syndrome (3%). Levitra demonstrated a clinically meaningful and statistically levitra patient information leaflets increase in the overall per-patient rate of maintenance of erection to successful intercourse (SEP3) (49% on 10 mg, 54% on 20 mg Levitra compared to 23% on placebo; p <0.0001). Contact your doctor or seek emergency medical attention if your erection is painful or lasts longer than 4 hours. Excretion: The total body clearance of vardenafil is 56 L/h, and the terminal half-life of vardenafil and its primary metabolite (M1) is approximately 4-5 hours. Taking Levitra with a nitrate medicine can cause a serious decrease in blood pressure, leading to fainting, stroke, or heart attack. Follow your doctor's instructions. Concomitant Medications: The dosage of Levitra may require adjustment in patients receiving potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, atazanavir, and clarithromycin as well as in other patients receiving moderate CYP3A4 inhibitors such as erythromycin (see WARNINGS, PRECAUTIONS, Drug Interactions).